Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2533]

Two trials show efficacy for enzalutamide in prostate cancer

Two trials show efficacy for enzalutamide in prostate cancer

Younger men need to review priorities with time after surgery for high-risk prostate cancer

Younger men need to review priorities with time after surgery for high-risk prostate cancer

Rare African bush may help kidney cancer treatment

Rare African bush may help kidney cancer treatment

Naproxen plus acid-blocking drug shows promise in preventing bladder cancer

Naproxen plus acid-blocking drug shows promise in preventing bladder cancer

Breast cancer risk may be increased in women who have first-degree relatives with a history of prostate cancer

Breast cancer risk may be increased in women who have first-degree relatives with a history of prostate cancer

Do healthy-looking prostate cancer cells mask deadly cancer-causing mutations?

Do healthy-looking prostate cancer cells mask deadly cancer-causing mutations?

ASCO GU: Early evidence of increase in higher-risk prostate cancers from 2011-2013

ASCO GU: Early evidence of increase in higher-risk prostate cancers from 2011-2013

ASCO GU: Active surveillance of intermediate-risk prostate cancer associated with decreased survival

ASCO GU: Active surveillance of intermediate-risk prostate cancer associated with decreased survival

ASCO GU: Adjuvant sorafenib and sunitinib do not improve outcomes in locally advanced kidney cancer

ASCO GU: Adjuvant sorafenib and sunitinib do not improve outcomes in locally advanced kidney cancer

ASCO GU: Androgen receptor abnormality may not be associated with primary resistance to taxane chemotherapy

ASCO GU: Androgen receptor abnormality may not be associated with primary resistance to taxane chemotherapy

More from ecancer